Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Applied Therapeutics

Nasdaq:APLT
Snowflake Description

Excellent balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
APLT
Nasdaq
$669M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
  • Applied Therapeutics has significant price volatility in the past 3 months.
APLT Share Price and Events
7 Day Returns
12.7%
NasdaqGM:APLT
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGM:APLT
0%
US Biotechs
-11.5%
US Market
APLT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Applied Therapeutics (APLT) 12.7% -26.9% 16.7% - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on APLT.
  • No trading data on APLT.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

APLT Value

 Is Applied Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Applied Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Applied Therapeutics.

NasdaqGM:APLT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:APLT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (0.3%))
1.138
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.138 * 5.44%)
7.93%

Discounted Cash Flow Calculation for NasdaqGM:APLT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Applied Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:APLT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.93%)
2020 -50.00 Analyst x1 -46.33
2021 -80.00 Analyst x1 -68.68
2022 -67.00 Analyst x1 -53.29
2023 -32.00 Analyst x1 -23.58
2024 47.00 Analyst x1 32.09
2025 71.47 Est @ 52.07% 45.22
2026 97.89 Est @ 36.97% 57.38
2027 123.74 Est @ 26.4% 67.20
2028 147.25 Est @ 19% 74.10
2029 167.60 Est @ 13.82% 78.14
Present value of next 10 years cash flows $162.00
NasdaqGM:APLT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $167.60 × (1 + 1.74%) ÷ (7.93% – 1.74%)
$2,755.19
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,755.19 ÷ (1 + 7.93%)10
$1,284.61
NasdaqGM:APLT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $162.00 + $1,284.61
$1,446.61
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,446.61 / 21.97
$65.85
NasdaqGM:APLT Discount to Share Price
Calculation Result
Value per share (USD) From above. $65.85
Current discount Discount to share price of $30.44
= -1 x ($30.44 - $65.85) / $65.85
53.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Applied Therapeutics is available for.
Intrinsic value
>50%
Share price is $30.44 vs Future cash flow value of $65.85
Current Discount Checks
For Applied Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Applied Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Applied Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Applied Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Applied Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:APLT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.55
NasdaqGM:APLT Share Price ** NasdaqGM (2020-03-27) in USD $30.44
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Applied Therapeutics.

NasdaqGM:APLT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:APLT Share Price ÷ EPS (both in USD)

= 30.44 ÷ -3.55

-8.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Applied Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Applied Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:APLT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-0.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Applied Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Applied Therapeutics's assets?
Raw Data
NasdaqGM:APLT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.76
NasdaqGM:APLT Share Price * NasdaqGM (2020-03-27) in USD $30.44
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:APLT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:APLT Share Price ÷ Book Value per Share (both in USD)

= 30.44 ÷ 1.76

17.3x

* Primary Listing of Applied Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Applied Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Applied Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Applied Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

APLT Future Performance

 How is Applied Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-0.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Applied Therapeutics expected to grow at an attractive rate?
  • Unable to compare Applied Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Applied Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Applied Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:APLT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:APLT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -0.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:APLT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:APLT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 179 -15 1
2023-12-31 81 -88 1
2022-12-31 30 -116 1
2021-12-31 2 -107 2
2020-12-31 0 -72 2
2020-03-28
NasdaqGM:APLT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -36 -46
2019-09-30 -30 -35
2019-06-30 -24 -28
2019-03-31 -17 -23
2018-12-31 -11 -17
2017-12-31 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Applied Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Applied Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:APLT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Applied Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:APLT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.45 -0.45 -0.45 1.00
2023-12-31 -2.85 -2.85 -2.85 1.00
2022-12-31 -4.00 -4.00 -4.00 1.00
2021-12-31 -4.55 -3.41 -5.88 3.00
2020-12-31 -3.22 -3.02 -3.42 2.00
2020-03-28
NasdaqGM:APLT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.55
2019-09-30 -2.90
2019-06-30 -3.69
2019-03-31 -4.17
2018-12-31 -3.01
2017-12-31 -0.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Applied Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Applied Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Applied Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

APLT Past Performance

  How has Applied Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Applied Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Applied Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Applied Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Applied Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Applied Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Applied Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:APLT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -45.51 13.23 32.35
2019-09-30 -34.60 9.96 23.94
2019-06-30 -28.17 7.26 19.21
2019-03-31 -22.92 3.48 16.90
2018-12-31 -16.52 2.05 11.47
2017-12-31 -4.28 0.58 3.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Applied Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Applied Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Applied Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Applied Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Applied Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

APLT Health

 How is Applied Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Applied Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Applied Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Applied Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Applied Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Applied Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Applied Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:APLT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 32.61 0.00 38.85
2019-09-30 30.75 0.00 32.95
2019-06-30 40.00 0.00 41.08
2019-03-31 10.54 0.00 14.69
2018-12-31 15.82 0.00 18.75
2017-12-31 2.29 0.00 3.28
  • Applied Therapeutics has no debt.
  • Applied Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Applied Therapeutics has sufficient cash runway for 1.1 years based on current free cash flow.
  • Applied Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 81.8% each year.
X
Financial health checks
We assess Applied Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Applied Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

APLT Dividends

 What is Applied Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Applied Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Applied Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Applied Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Applied Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:APLT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:APLT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Applied Therapeutics has not reported any payouts.
  • Unable to verify if Applied Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Applied Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Applied Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Applied Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Applied Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Applied Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Applied Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

APLT Management

 What is the CEO of Applied Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shoshana Shendelman
COMPENSATION $11,589,972
AGE 41
CEO Bio

Dr. Shoshana Shendelman, PhD is the Founder of Applied Therapeutics Inc. and serves as its Chairman, President, Chief Executive Officer and Secretary. Dr. Shendelman has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, Dr. Shendelman founded Clearpoint Strategy Group, a boutique strategic advisory firm in NYC, where she serves as a Senior Advisor. Dr. Shendelman has directed products through early and late stage development, from conceptual design to product launch for clients including top 10 pharmaceutical companies, biotech start-ups, and VC firms. She received her doctorate from Columbia University in Cellular, Molecular, and Biophysical Studies (CMBS), where her graduate work focused on neuronal stem cell differentiation and molecular mechanisms of Parkinson’s disease.

CEO Compensation
  • Shoshana's compensation has increased whilst company is loss making.
  • Shoshana's remuneration is higher than average for companies of similar size in United States of America.
Management Team

Shoshana Shendelman

TITLE
Chairman
COMPENSATION
$12M
AGE
41

Mark Vignola

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
42
TENURE
0.9 yrs

Riccardo Perfetti

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
60
TENURE
1.6 yrs

Adam Hansard

TITLE
Chief Commercial Officer
Board of Directors Tenure

Average tenure and age of the Applied Therapeutics board of directors in years:

0.9
Average Tenure
62
Average Age
  • The average tenure for the Applied Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Shoshana Shendelman

TITLE
Chairman
COMPENSATION
$12M
AGE
41

Donald Landry

TITLE
Chairman of Scientific Advisory Board
AGE
64

Teena Lerner

TITLE
Independent Director
COMPENSATION
$279K
AGE
61
TENURE
3 yrs

Jay Skyler

TITLE
Independent Director
COMPENSATION
$161K
AGE
72
TENURE
0.9 yrs

Stacy Kanter

TITLE
Independent Director
COMPENSATION
$164K
AGE
60
TENURE
0.8 yrs

Gregg Stone

TITLE
Member of Scientific Advisory Board
AGE
62

Larry Steinman

TITLE
Member of Scientific Advisory Board
AGE
71

Roxana Mehran

TITLE
Member of Scientific Advisory Board

Roy Freeman

TITLE
Member of Scientific Advisory Board

Andrew Wasmuth

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Applied Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
29. Jan 20 Buy Joel Marcus Individual 28. Jan 20 28. Jan 20 500 $45.50 $22,750
29. Jan 20 Buy Stacy Kanter Individual 28. Jan 20 28. Jan 20 6,500 $45.50 $295,750
21. May 19 Buy Alexandria Venture Investments, LLC Company 16. May 19 16. May 19 975,000 $10.00 $9,750,000
20. May 19 Buy Joel Marcus Individual 16. May 19 16. May 19 150,000 $10.00 $1,500,000
20. May 19 Buy Shoshana Shendelman Individual 16. May 19 16. May 19 125,000 $10.00 $1,250,000
X
Management checks
We assess Applied Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Applied Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

APLT News

Simply Wall St News

Have Insiders Been Buying Applied Therapeutics, Inc. (NASDAQ:APLT) Shares This Year?

While Applied Therapeutics insiders bought shares last year, they didn't sell. … NasdaqGM:APLT Recent Insider Trading, August 14th 2019 Insiders at Applied Therapeutics Have Bought Stock Recently It's good to see that Applied Therapeutics insiders have made notable investments in the company's shares. … When combined with notable insider ownership, these factors suggest Applied Therapeutics insiders are well aligned, and that they may think the share price is too low.

Simply Wall St -

APLT Company Info

Description

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company’s preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Details
Name: Applied Therapeutics, Inc.
APLT
Exchange: NasdaqGM
Founded: 2016
$668,744,791
21,969,277
Website: http://www.appliedtherapeutics.com
Address: Applied Therapeutics, Inc.
545 Fifth Avenue,
Suite 1400,
New York,
New York, 10017,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM APLT Common Stock Nasdaq Global Market US USD 14. May 2019
DB 2UV Common Stock Deutsche Boerse AG DE EUR 14. May 2019
Number of employees
Current staff
Staff numbers
11
Applied Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:58
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.